ArticleJournal of clinical oncology : official journal of the American Society of Clinical Oncology2014
Association of age with survival in patients with metastatic colorectal cancer: analysis from the ARCAD Clinical Trials Program.
Article in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 94 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
94 citing papers in PubMed, 5 syntheses or guidelines pooled it.
- Delphi Initiative for Early-Onset Colorectal Cancer (DIRECt) International Management Guidelines.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2023Guideline
- The prognostic utility of pre-treatment neutrophil-to-lymphocyte-ratio (NLR) in colorectal cancer: A systematic review and meta-analysis.Cancer medicine · 2021Pooled it
- Effect of age on the effectiveness of the first-line standard of care treatment in patients with metastatic colorectal cancer: systematic review of observational studies.Journal of cancer research and clinical oncology · 2019Pooled it
- Impact of the addition of bevacizumab, oxaliplatin, or irinotecan to fluoropyrimidin in the first-line treatment of metastatic colorectal cancer in elderly patients.International journal of colorectal disease · 2018Pooled it
- Doublet chemotherapy vs. single-agent therapy with 5FU in elderly patients with metastatic colorectal cancer. a meta-analysis.International journal of colorectal disease · 2015Pooled it
- The effect of geriatric intervention in frail elderly patients receiving chemotherapy for colorectal cancer: a randomized trial (GERICO).BMC cancer · 2017Trial
- Trial
- Early-onset colorectal cancer in patients under 30: a case series from Tanzania highlighting an emerging epidemiological shift.Journal of surgical case reports · 2026Article
- Socioeconomic disparities in survival of patients with superficial colorectal cancer.Discover oncology · 2026Article
- Association of Primary Tumor Resection with Survival in De Novo Stage IV Colorectal Cancer: A Retrospective Cohort Study with Propensity Score Matching.Current oncology (Toronto, Ont.) · 2026Article
- Clusters of Anthropometric Features in Colorectal Cancer Patients with Synchronous Metastases and Their Association with Overall Survival and RAS Mutation.Journal of gastrointestinal cancer · 2026Article
- Survival benefits of immunotherapy combined with chemoradiotherapy in metastatic colorectal cancer: an analysis based on data from the SEER database.Open medicine (Warsaw, Poland) · 2026Article
- Survival Outcomes and Prognostic Factors in Patients with Metastatic Colorectal Cancer Treated First-Line mFOLFOXIRI Plus Bevacizumab: A Real-World Study in Vietnam.OncoTargets and therapy · 2026Article
- Imaging of young-onset colorectal cancer: what the radiologist needs to know.Abdominal radiology (New York) · 2025Review
- Article
- Epigenetic Modulation, Intratumoral Microbiome, and Immunity in Early-Onset Colorectal Cancer.Cancer research communications · 2025Article
- Development and Validation of anJCO clinical cancer informatics · 2025Article
- Early onset metastatic colorectal cancer patients as a distinctive clinical and molecular phenomenon.British journal of cancer · 2025Article
- Mutational and co-mutational landscape of early onset colorectal cancer.Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals · 2025Article
- Evaluating the efficacy of stereotactic radiotherapy for metastatic colorectal cancer: A retrospective review of clinical outcomes.Journal of radiosurgery and SBRT · 2025Article
34 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
purposeThis study addressed whether age is prognostic for overall survival (OS) or progression-free survival (PFS) in patients with metastatic colorectal cancer (mCRC). PATIENTS AND
methodsA total of 20,023 patients from 24 first-line clinical trials in the ARCAD (Aide et Recherche en Cancérologie Digestive) database were analyzed. Primary age effects and interactions with age,sex, performance status (PS), and metastatic site were modeled using Cox proportional hazards stratified by treatment arm within study.
resultsOf total patients, 3,051 (15%) were age < or =50 years. Age was prognostic for both OS (P < .001)and PFS (P < .001), with U-shaped risk (i.e., highest risk was evident in youngest and oldest patients). Relative to patients of middle age, the youngest patients experienced 19% (95% CI, 7% to 33%) increased risk of death and 22% (95% CI, 10% to 35%) increased risk of progression. The oldest patients experienced 42% (95% CI, 31% to 54%) increased risk of death and 15% (95% CI, 7% to 24%) increased risk of progression or death. This relationship was more pronounced in the first year of follow-up. Age remained marginally significant for OS (P = .08) when adjusted forPS, sex, and presence of liver, lung, or peritoneal metastases, and age was significant in an adjusted model for PFS (P = .005). The age effect did not differ by site of metastatic disease, year of enrollment, type of therapy received, or biomarker mutational status.
conclusionYounger and older age are associated with poorer OS and PFS among treated patients with mCRC. Younger and older patients may represent higher-risk populations, and additional studies are warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.